Which has preferable earnings and valuation, BLLN or PSNL?

Billiontoone has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $305.11M 19.00 $7.45M $0.55 229.24 Personalis $69.65M 17.71 -$81.27M -$1.02 N/A

Does the media prefer BLLN or PSNL?

In the previous week, Personalis had 27 more articles in the media than Billiontoone. MarketBeat recorded 30 mentions for Personalis and 3 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.63 beat Personalis' score of 0.22 indicating that Billiontoone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 8 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SHC or PSNL?

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.25 $77.94M $0.41 42.32 Personalis $69.65M 17.71 -$81.27M -$1.02 N/A

Is SHC or PSNL more profitable?

Sotera Health has a net margin of 9.91% compared to Personalis' net margin of -148.11%. Sotera Health's return on equity of 39.73% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% Personalis -148.11% -43.52% -32.92%

Does the media refer more to SHC or PSNL?

In the previous week, Personalis had 22 more articles in the media than Sotera Health. MarketBeat recorded 30 mentions for Personalis and 8 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.25 beat Personalis' score of 0.22 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 8 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, RDNT or PSNL?

RadNet has higher revenue and earnings than Personalis. RadNet is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.37 -$18.65M -$0.18 N/A Personalis $69.65M 17.71 -$81.27M -$1.02 N/A

Is RDNT or PSNL more profitable?

RadNet has a net margin of -0.66% compared to Personalis' net margin of -148.11%. RadNet's return on equity of 2.77% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.66% 2.77% 0.97% Personalis -148.11% -43.52% -32.92%

Does the media favor RDNT or PSNL?

In the previous week, Personalis had 21 more articles in the media than RadNet. MarketBeat recorded 30 mentions for Personalis and 9 mentions for RadNet. RadNet's average media sentiment score of 1.35 beat Personalis' score of 0.22 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 8 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher valuation & earnings, VCYT or PSNL?

Veracyte has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 8.73 $66.35M $1.09 51.94 Personalis $69.65M 17.71 -$81.27M -$1.02 N/A

Is VCYT or PSNL more profitable?

Veracyte has a net margin of 16.25% compared to Personalis' net margin of -148.11%. Veracyte's return on equity of 9.07% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% Personalis -148.11% -43.52% -32.92%

Does the media favor VCYT or PSNL?

In the previous week, Personalis had 25 more articles in the media than Veracyte. MarketBeat recorded 30 mentions for Personalis and 5 mentions for Veracyte. Veracyte's average media sentiment score of 0.90 beat Personalis' score of 0.22 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 8 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to PSNL or CAI?

In the previous week, Personalis had 28 more articles in the media than Caris Life Sciences. MarketBeat recorded 30 mentions for Personalis and 2 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.88 beat Personalis' score of 0.22 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 8 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Personalis (PSNL) Competitors

$11.78 -0.44 (-3.60%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$11.84 +0.06 (+0.51%)

As of 07/24/2026 07:34 PM Eastern

Compare

PSNL vs. BLLN, SHC, RDNT, VCYT, and CAI

Should you buy Personalis stock or one of its competitors? MarketBeat compares Personalis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Personalis include Billiontoone (BLLN), Sotera Health (SHC), RadNet (RDNT), Veracyte (VCYT), and Caris Life Sciences (CAI). These companies are all part of the "healthcare" industry.

How does Personalis compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

In the previous week, Personalis had 27 more articles in the media than Billiontoone. MarketBeat recorded 30 mentions for Personalis and 3 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.63 beat Personalis' score of 0.22 indicating that Billiontoone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	8 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Billiontoone currently has a consensus target price of $126.00, suggesting a potential downside of 0.06%. Personalis has a consensus target price of $14.25, suggesting a potential upside of 20.97%. Given Personalis' higher probable upside, analysts plainly believe Personalis is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Billiontoone has a net margin of 0.00% compared to Personalis' net margin of -148.11%. Billiontoone's return on equity of 0.00% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
Personalis	-148.11%	-43.52%	-32.92%

Billiontoone has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	19.00	$7.45M	$0.55	229.24
Personalis	$69.65M	17.71	-$81.27M	-$1.02	N/A

61.9% of Personalis shares are held by institutional investors. 50.2% of Billiontoone shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Billiontoone beats Personalis on 12 of the 15 factors compared between the two stocks.

How does Personalis compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Sotera Health has a net margin of 9.91% compared to Personalis' net margin of -148.11%. Sotera Health's return on equity of 39.73% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
Personalis	-148.11%	-43.52%	-32.92%

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.25	$77.94M	$0.41	42.32
Personalis	$69.65M	17.71	-$81.27M	-$1.02	N/A

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sotera Health presently has a consensus price target of $20.25, suggesting a potential upside of 16.71%. Personalis has a consensus price target of $14.25, suggesting a potential upside of 20.97%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Sotera Health has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Personalis has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

In the previous week, Personalis had 22 more articles in the media than Sotera Health. MarketBeat recorded 30 mentions for Personalis and 8 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.25 beat Personalis' score of 0.22 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	8 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Sotera Health beats Personalis on 12 of the 16 factors compared between the two stocks.

How does Personalis compare to RadNet?

RadNet (NASDAQ:RDNT) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

77.9% of RadNet shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 5.6% of RadNet shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Personalis had 21 more articles in the media than RadNet. MarketBeat recorded 30 mentions for Personalis and 9 mentions for RadNet. RadNet's average media sentiment score of 1.35 beat Personalis' score of 0.22 indicating that RadNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	8 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

RadNet presently has a consensus target price of $87.43, indicating a potential upside of 42.00%. Personalis has a consensus target price of $14.25, indicating a potential upside of 20.97%. Given RadNet's stronger consensus rating and higher possible upside, equities analysts clearly believe RadNet is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

RadNet has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Personalis has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

RadNet has a net margin of -0.66% compared to Personalis' net margin of -148.11%. RadNet's return on equity of 2.77% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
Personalis	-148.11%	-43.52%	-32.92%

RadNet has higher revenue and earnings than Personalis. RadNet is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.37	-$18.65M	-$0.18	N/A
Personalis	$69.65M	17.71	-$81.27M	-$1.02	N/A

Summary

RadNet beats Personalis on 13 of the 17 factors compared between the two stocks.

How does Personalis compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, Personalis had 25 more articles in the media than Veracyte. MarketBeat recorded 30 mentions for Personalis and 5 mentions for Veracyte. Veracyte's average media sentiment score of 0.90 beat Personalis' score of 0.22 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	8 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Veracyte currently has a consensus price target of $55.88, suggesting a potential downside of 1.30%. Personalis has a consensus price target of $14.25, suggesting a potential upside of 20.97%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Veracyte has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Personalis has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market.

Veracyte has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	8.73	$66.35M	$1.09	51.94
Personalis	$69.65M	17.71	-$81.27M	-$1.02	N/A

61.9% of Personalis shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 4.2% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Veracyte has a net margin of 16.25% compared to Personalis' net margin of -148.11%. Veracyte's return on equity of 9.07% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Personalis	-148.11%	-43.52%	-32.92%

Summary

Veracyte beats Personalis on 11 of the 17 factors compared between the two stocks.

How does Personalis compare to Caris Life Sciences?

Personalis (NASDAQ:PSNL) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Caris Life Sciences has a net margin of 3.75% compared to Personalis' net margin of -148.11%. Caris Life Sciences' return on equity of 98.28% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-43.52%	-32.92%
Caris Life Sciences	3.75%	98.28%	48.87%

Personalis currently has a consensus price target of $14.25, suggesting a potential upside of 20.97%. Caris Life Sciences has a consensus price target of $26.11, suggesting a potential upside of 68.24%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Personalis had 28 more articles in the media than Caris Life Sciences. MarketBeat recorded 30 mentions for Personalis and 2 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.88 beat Personalis' score of 0.22 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	8 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Caris Life Sciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	17.71	-$81.27M	-$1.02	N/A
Caris Life Sciences	$812.03M	5.40	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Personalis on 11 of the 15 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.23B	$5.72B	$7.06B	$12.20B
Dividend Yield	N/A	0.71%	2.67%	9.41%
P/E Ratio	-11.55	8.74	27.14	23.63
Price / Sales	17.71	21.99	582.30	111.98
Price / Cash	N/A	7.89	49.81	58.78
Price / Book	4.01	4.10	10.28	6.01
Net Income	-$81.27M	$99.67M	$3.60B	$331.99M
7 Day Performance	-23.46%	-5.64%	-1.27%	-0.63%
1 Month Performance	-9.52%	-4.66%	-1.67%	-3.04%
1 Year Performance	81.51%	94.85%	18.25%	13.30%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSNL Personalis	3.3493 of 5 stars	$11.78 -3.6%	$14.25 +21.0%	+81.5%	$1.23B	$69.65M	N/A	400	Analyst Downgrade
BLLN Billiontoone	2.1291 of 5 stars	$125.14 -4.0%	$126.00 +0.7%	N/A	$5.99B	$354.54M	227.53	620
SHC Sotera Health	3.8277 of 5 stars	$17.42 -1.9%	$20.25 +16.2%	+41.1%	$5.06B	$1.16B	42.49	3,000	News Coverage Positive News
RDNT RadNet	3.6065 of 5 stars	$60.68 -2.4%	$87.43 +44.1%	+7.2%	$4.89B	$2.04B	N/A	11,264	News Coverage
VCYT Veracyte	1.9355 of 5 stars	$57.26 -3.2%	$55.88 -2.4%	+124.2%	$4.72B	$517.15M	52.53	790	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. BLLN, SHC, RDNT, VCYT, and CAI

How does Personalis compare to Billiontoone?

Summary

How does Personalis compare to Sotera Health?

Summary

How does Personalis compare to RadNet?

Summary

How does Personalis compare to Veracyte?

Summary

How does Personalis compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. BLLN, SHC, RDNT, VCYT, and CAI

How does Personalis compare to Billiontoone?

Does the media prefer BLLN or PSNL?

Do analysts prefer BLLN or PSNL?

Is BLLN or PSNL more profitable?

Which has preferable earnings and valuation, BLLN or PSNL?

Do insiders and institutionals have more ownership in BLLN or PSNL?

Summary

How does Personalis compare to Sotera Health?

Is SHC or PSNL more profitable?

Which has stronger valuation and earnings, SHC or PSNL?

Do institutionals & insiders have more ownership in SHC or PSNL?

Do analysts rate SHC or PSNL?

Which has more risk & volatility, SHC or PSNL?

Does the media refer more to SHC or PSNL?

Summary

How does Personalis compare to RadNet?

Do insiders & institutionals have more ownership in RDNT or PSNL?

Does the media favor RDNT or PSNL?

Do analysts prefer RDNT or PSNL?

Which has more risk and volatility, RDNT or PSNL?

Is RDNT or PSNL more profitable?

Which has preferable earnings and valuation, RDNT or PSNL?

Summary

How does Personalis compare to Veracyte?

Does the media favor VCYT or PSNL?

Do analysts prefer VCYT or PSNL?

Which has more volatility & risk, VCYT or PSNL?

Which has higher valuation & earnings, VCYT or PSNL?

Do insiders and institutionals hold more shares of VCYT or PSNL?

Is VCYT or PSNL more profitable?

Summary

How does Personalis compare to Caris Life Sciences?

Is PSNL or CAI more profitable?

Do analysts prefer PSNL or CAI?

Does the media refer more to PSNL or CAI?

Do insiders & institutionals have more ownership in PSNL or CAI?

Which has better valuation & earnings, PSNL or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools